Bethany Sensenig was appointed Director of Alpha Cognition Inc. As of November 8, 2026, Alpha Cognition Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 20, 2026 to June 23, 2026, naming 1 appointment (Form 8-K, April 20, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Alpha Cognition Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-06-23
- · In / out: Reported · Person: not named in the filing · 8-K/A, 2026-05-01
- · In / out: In · Person: Bethany Sensenig · Role: Director · 8-K, 2026-04-20
Alpha Cognition Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-20 to 2026-06-23. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Alpha Cognition Inc. files it.
Also on the record for Alpha Cognition Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 23, 2026 | Stake report, Schedule 13G, by James E. Besser | 7.4% of the class | 5%+ stakes | Source |
| July 24, 2026 | Stake report, Schedule 13G/A, by Opaleye Management Inc. | 14.22% of the class | 5%+ stakes | Source |
| June 29, 2026 | Stake report, Schedule 13G/A, by Opaleye Management Inc. | 13.3% of the class | 5%+ stakes | Source |
| May 22, 2026 | Stake report, Schedule 13G/A, by Opaleye Management Inc. | 12.03% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G/A, by James E. Besser | 4.9% of the class | 5%+ stakes | Source |
| May 11, 2026 | Stake report, Schedule 13G/A, by Opaleye Management Inc. | 11.77% of the class | 5%+ stakes | Source |
| March 4, 2026 | Stake report, Schedule 13G/A, by Opaleye Management Inc. | 11% of the class | 5%+ stakes | Source |
| February 20, 2026 | Stake report, Schedule 13G/A, by Opaleye Management Inc. | 10.09% of the class | 5%+ stakes | Source |
| February 20, 2026 | Stake report, Schedule 13G/A, by Opaleye Management Inc. | 10.43% of the class | 5%+ stakes | Source |
| February 19, 2026 | Stake report, Schedule 13G, by Funicular Funds, LP | 5.1% of the class | 5%+ stakes | Source |
| February 18, 2026 | Stake report, Schedule 13G/A, by Funicular Funds, LP | 4.9% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by MANCHESTER MANAGEMENT COMPANY, LLC | 5.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Alpha Cognition Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Alpha Cognition Inc. and the records around it.
Alpha Cognition Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
- Who owns it
Companies that share a holder
- Manchester Management Company, LLC also filed stake reports on 2 other companies: EUPRAXIA PHARMACEUTICALS INC. (Aug 2026), SANUWAVE Health, Inc. (Dec 2025)
- Funicular Funds, LP also filed stake reports on 10 other companies: AmpliTech Group, Inc. (Oct 2026), SYNLOGIC, INC. (Jul 2026), Rein Therapeutics, Inc. (May 2026)
- Opaleye Management Inc. also filed stake reports on 12 other companies: Codexis, Inc. (Nov 2026), Gossamer Bio, Inc. (Nov 2026), Pasithea Therapeutics Corp. (Nov 2026)
Watch Alpha Cognition Inc.
Get an email when Alpha Cognition Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Alpha Cognition Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Alpha Cognition Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Alpha Cognition Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 17 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-23 | Reported | not named in the filing | 8-K, 2026-06-23 | ||
| 2026-05-01 | Reported | not named in the filing | 8-K/A, 2026-05-01 | ||
| 2026-04-20 | In | Director | 8-K, 2026-04-20 |
Who leads Alpha Cognition Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Bethany Sensenig, appointed (filed 2026-04-20).
New leaders reset buying decisions — get the Full Report on Alpha Cognition Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Alpha Cognition Inc., with the record behind each one.
Find candidates like Director at Alpha Cognition Inc.Every change, in the filing's words
Reported
On June 16, 2026, following Alpha Cognition Inc.'s (the " Company ") 2026 annual meeting of stockholders on June 16, 2026 (the " Meeting "), the board of directors (the " Board ") of the Copmany appointed Dr. Robert Wills as non-executive Chair of the Board.
- Dr.Wills fills the vacancy left by Mr. Len Mertz who, as previously announced, did not stand for re-election as a director of the Company at the Meeting.
Reported
On April 28, 2026, the Board appointed Ms. Sensenig as a member of the Audit Committee of the Board and as a member of the Governance and Nomination Committee of the Board.
- Further, effective following the Company's upcoming annual meeting of shareholders on June 16, 2026, the Board has appointed Ms. Sensenig to be the Chair of the Audit Committee of the Board.
Appointed: Bethany Sensenig, Director
On April 15, 2026, the Board appointed Bethany Sensenig as a director of the Company.
- Ms. Sensenig was most recently Chief Financial Officer and Head of Operations at Radius Health, Inc (May 2024 to April 2026), a commercial stage biopharmaceutical company, where she played a critical leadership role in the growth, financial performance, and sale of the company.
- Prior to this, she served as Chief Financial Officer, and Interim CEO of 9 Meters Biopharma (Jan 2022 to July 2023), a clinical-stage biotechnology company.
- Preceding 9 Meters, Ms. Sensenig was Chief Financial Officer and Head of U.S. Operations at Minovia Therapeutics, Ltd. (June 2019 to Jan 2022), a clinical-stage biotechnology company, focused on rare diseases, where she led the company's business and financing strategy.
- She spent 13 years at Biogen Inc., a multinational biotechnology company, where she held several positions of increasing responsibility, the latest of which was Vice President of Finance and Commercial Operations.
- Ms. Sensenig has played key roles in numerous transactions, financings and acquisition-related deals throughout her career and had direct P&L accountability at Biogen for upwards of $1 billion in annual revenue across 30 countries spanning the U.S., Asia-Pacific, Latin America and Europe.
- Ms. Sensenig is also a member of the Board of Directors at Supernus Pharmaceuticals (NASDAQ: SUPN) and KalVista Pharmaceuticals (NASDAQ: KALV).
Tools for this story
Each opens in a new tab, filled in for Alpha Cognition Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.